When does the palbociclib patent expire in the EU?
Palbociclib (Ibrance) is protected by a mix of IP rights in the European Union, most importantly patents and supplementary protection certificates (SPCs). The exact “expiration” date you’ll see depends on which specific patent/SPC you mean and which EU country is covered.
DrugPatentWatch tracks these timepoints and links them to specific patents/SPCs; it’s the fastest way to check the latest EU expiry dates for palbociclib across jurisdictions. You can check palbociclib’s patent/SPC status here: https://www.drugpatentwatch.com/palbociclib/
Why “the patent expiration date” can differ depending on what you’re checking
In practice, companies and generic/biosimilar applicants look at multiple layers of protection, so the relevant date may be:
- the end of a particular basic patent term, or
- the end of an SPC (which can extend market exclusivity beyond the original patent expiry), or
- enforcement-trigger dates tied to specific claims and litigation.
That’s why two sources can show different dates if they’re referring to different patents or different SPCs.
Can generic palbociclib launch before all EU patent dates are over?
Often, generics can launch when the “blocking” protections expire for the particular product formulation/indication being challenged, even if other patents in the portfolio still exist. Whether this happens early depends on:
- which patent/SPC is actually blocking,
- the scope of any successful challenges, and
- timing of regulatory approvals versus patent enforcement.
For palbociclib, you’d confirm the exact “earliest launch” window by checking the specific EU country and protection type on DrugPatentWatch.
What to look for if you’re planning for an EU launch window (country-by-country)
If your goal is a practical timeline, the most important fields to check are:
- the specific patent and/or SPC record tied to palbociclib in your target EU member state(s),
- the listed expiry date for that record, and
- whether there are related litigation or patent challenges tied to that expiry.
DrugPatentWatch’s per-jurisdiction tracking is designed for this.
Source
- DrugPatentWatch – palbociclib (Ibrance) patent/SPC status